Key Points
- Chairman Morgan Lee Lekstrom bought 147,000 shares of Biosig Technologies at an average price of $1.04, spending about $152,880 and boosting his stake by 120% to 269,500 shares.
- Lekstrom had also sold 12,759 shares in April at an average price of $1.07, showing recent insider trading activity on both sides.
- STEX was up 3.7% and opened at $1.13, while analysts currently rate the stock Hold on average with a consensus target price of $8.00.
Biosig Technologies, Inc. (NASDAQ:STEX - Get Free Report) Chairman Morgan Lee Lekstrom bought 147,000 shares of Biosig Technologies stock in a transaction dated Thursday, May 21st. The shares were bought at an average cost of $1.04 per share, for a total transaction of $152,880.00. Following the completion of the acquisition, the chairman owned 269,500 shares in the company, valued at $280,280. This represents a 120.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Morgan Lee Lekstrom also recently made the following trade(s):
- On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The stock was sold at an average price of $1.07, for a total value of $13,652.13.
Biosig Technologies Trading Up 3.7%
STEX opened at $1.13 on Friday. The firm has a market cap of $204.69 million, a price-to-earnings ratio of -0.12 and a beta of 1.58. Biosig Technologies, Inc. has a 52-week low of $0.70 and a 52-week high of $14.11. The stock's fifty day moving average is $1.19.
Biosig Technologies (NASDAQ:STEX - Get Free Report) last released its earnings results on Thursday, May 14th. The company reported $999.00 earnings per share (EPS) for the quarter.
Analyst Upgrades and Downgrades
STEX has been the topic of a number of recent analyst reports. Needham & Company LLC decreased their target price on Biosig Technologies from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Thursday. Wall Street Zen cut shares of Biosig Technologies from a "hold" rating to a "strong sell" rating in a report on Sunday, April 5th. Finally, Weiss Ratings raised shares of Biosig Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, May 1st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $8.00.
Read Our Latest Stock Analysis on STEX
About Biosig Technologies
(
Get Free Report)
Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.
Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
